EP0888381A4 - Targeted therapeutic or diagnostic agents and methods of making and using same - Google Patents

Targeted therapeutic or diagnostic agents and methods of making and using same

Info

Publication number
EP0888381A4
EP0888381A4 EP96945796A EP96945796A EP0888381A4 EP 0888381 A4 EP0888381 A4 EP 0888381A4 EP 96945796 A EP96945796 A EP 96945796A EP 96945796 A EP96945796 A EP 96945796A EP 0888381 A4 EP0888381 A4 EP 0888381A4
Authority
EP
European Patent Office
Prior art keywords
making
methods
same
diagnostic agents
targeted therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96945796A
Other languages
German (de)
French (fr)
Other versions
EP0888381A1 (en
Inventor
Edwin L Madison
Jeffrey W Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of EP0888381A1 publication Critical patent/EP0888381A1/en
Publication of EP0888381A4 publication Critical patent/EP0888381A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP96945796A 1995-12-21 1996-12-19 Targeted therapeutic or diagnostic agents and methods of making and using same Ceased EP0888381A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US902895P 1995-12-21 1995-12-21
US9028P 1995-12-21
PCT/US1996/020577 WO1997039021A1 (en) 1995-12-21 1996-12-19 Targeted therapeutic or diagnostic agents and methods of making and using same

Publications (2)

Publication Number Publication Date
EP0888381A1 EP0888381A1 (en) 1999-01-07
EP0888381A4 true EP0888381A4 (en) 2001-10-17

Family

ID=21735166

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96945796A Ceased EP0888381A4 (en) 1995-12-21 1996-12-19 Targeted therapeutic or diagnostic agents and methods of making and using same

Country Status (5)

Country Link
EP (1) EP0888381A4 (en)
JP (1) JP2000506854A (en)
AU (1) AU1821397A (en)
CA (1) CA2241051A1 (en)
WO (1) WO1997039021A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
RU2002109215A (en) * 1999-09-08 2003-12-10 Байер Акциенгезельшафт (De) Integrin-induced effects on drug site
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
EP1381396B1 (en) 2001-04-23 2009-04-01 Mallinckrodt Inc. Tc and re labeled radioactive glycosylated octreotide derivatives
US20090317329A2 (en) * 2005-07-05 2009-12-24 Baker Idi Heart & Diabetes Institute Holdings Limited Anticoagulation agent and uses thereof
CA2671581A1 (en) * 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339445C (en) * 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
DE69123241T2 (en) * 1990-12-14 1997-04-17 Cell Genesys Inc CHIMERIC CHAINS FOR TRANSDUCTING RECEPTOR-RELATED SIGNAL PATHS
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BODE, CHRISTOPH ET AL: "Platelet - targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation", CIRCULATION (1991), 84(2), 805-13, XP001010586 *
DEWERCHIN, M. ET AL: "Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo", BLOOD (1991), 78(4), 1005-18, XP001010583 *
HASKEL E.J. ET AL: "Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.", CIRCULATION, (1991) 83/3 (1048-1056)., XP000993163 *
NEBLOCK, DONALD S. ET AL: "Conjugation and evaluation of 7E3 x P4B6, a chemically crosslinked bispecific F(ab')2 antibody which inhibits platelet aggregation and localizes tissue plasminogen activator to the platelet surface", BIOCONJUGATE CHEM. (1992), 3(2), 126-31, XP002173015 *
See also references of WO9739021A1 *
SMITH, JEFFREY W. ET AL: "Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin.alpha.IIb.beta.3", J. BIOL. CHEM. (1995), 270(51), 30486-90, XP002173014 *
SWENSON, S. (1) ET AL: "A platelet targeted thrombolytic agent: Covalent modification with a platelet avid peptide.", FASEB JOURNAL, (1997) VOL. 11, NO. 9, PP. A1401. MEETING INFO.: 17TH INTERNATIONAL CONGRESS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY IN CONJUNCTION WITH THE ANNUAL MEETING OF THE AMERICAN SOCIETY FO BIOCHEMISTRY AND MOLECULAR BIOLOGY SAN FRANCISCO, CALI, XP000993094 *

Also Published As

Publication number Publication date
WO1997039021A1 (en) 1997-10-23
EP0888381A1 (en) 1999-01-07
CA2241051A1 (en) 1997-10-23
JP2000506854A (en) 2000-06-06
AU1821397A (en) 1997-11-07

Similar Documents

Publication Publication Date Title
EP0959908A4 (en) Novel targeted contrast agents for diagnostic and therapeutic use
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
PL330235A1 (en) Derivatives of spiropiperidine and their application as therapeutic agents
PL323087A1 (en) Methods of and formulations for modulating human sexual response
EP0831904A4 (en) Treatment and diagnosis of prostate cancer
ZA967029B (en) Versatile stereotactic device and methods of use
EP1129217A4 (en) Compositions and methods of disease diagnosis and therapy
GB9412711D0 (en) Medical use of bromelain
ZA96610B (en) Preparation of n-aryl and n-hetaryhydroxylamines
EP0888381A4 (en) Targeted therapeutic or diagnostic agents and methods of making and using same
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
ZA971607B (en) Methods of treatment of allergic diseases
GB9526691D0 (en) Medical use of proteases
PL322002A1 (en) Variants of human dnase i
EP1009433A4 (en) Therapeutic composition and method of treatment
ZA951485B (en) Medical application of bromelain
EP0833641A4 (en) Treatment and prevention of prostatic disease
PL312146A1 (en) Novel acylated pseudopetides with thrifluoromethy-substituted 2-azabicyclooctane, method of obtaining and therapeutic agents containing them
EP1015559A4 (en) Human regeneration-associated serpin-1 (rasp-1) and methods of use
GB9516572D0 (en) Prevention and/or treatment of disease
IL123509A0 (en) Therapeutic lipidic vesicles methods of use and compositions
GB9523066D0 (en) Compounds and their therapeutic use
PL312147A1 (en) Novel acylated pseudopeptides with thrifluoromethyl-substituted 2-azabicyclooctane, method of obtaining and therapeutic agents containing them
GB9525891D0 (en) Therapeutic agents and their preparation
ZA968902B (en) Methods and compositions for treatment of diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK FR GB IT LI NL SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 1/00 A, 7C 07K 14/00 B, 7C 07K 16/00 B, 7C 07K 17/00 B, 7C 12P 21/02 B, 7C 12P 21/04 B, 7C 12P 21/08 B, 7A 61K 39/395 B, 7A 61K 39/40 B, 7A 61K 39/42 B, 7A 61K 47/48 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010904

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE DK FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20020419

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20050417